What is claimed is:

1. A method for freezing a cell aggregate including neural cells and having a three-dimensional structure, which comprises following steps (1) and (2):

(1) contacting the cell aggregate including neural cells and having the three-dimensional structure with a preservation solution at 0°C to 30°C prior to freezing to prepare a preservation solution-soaked cell aggregate; and

(2) cooling the preservation solution-soaked cell aggregate obtained in step (1) from a temperature at least about 5°C higher than the freezing point of the preservation solution to a temperature about 5°C lower than the freezing point at an average cooling speed of 2 to 7 °C/min to freeze the cell aggregate.

2. The method according to claim 1, wherein the average cooling speed in step (2) is 3 to 7 °C/min.

3. The method according to claim 1 or 2, wherein the cell aggregate is contacted with the preservation solution for 15 minutes to 90 minutes, preferably 15 minutes to 60 minutes in step (1).

4. The method according to any one of claims 1 to 3, wherein the preservation solution has the freezing point of from -1°C to -10°C.

5. The method according to any one of claims 1 to 4, wherein the preservation solution is an aqueous solution comprising 7% to 12% of dimethyl sulfoxide and/or propylene glycol, and step (2) is a step of cooling from 0 ± 5°C to -

30 ± 5℃ at an average cooling speed of 2 to 5 ℃/min.

6. The method according to any one of claims 1 to 5, wherein the average cooling speed in step (2) is 3 to 5 ℃/min.

7. The method according to any one of claims 1 to 6, wherein the method further comprises a following step (3):

(3) cooling the frozen cell aggregate obtained in step (2) to −50℃ or lower.

8. The method according to any one of claims 1 to 7, wherein the cell aggregate including neural cells is a cell aggregate including neural cells derived from pluripotent stem cells.

9. The method according to any one of claims 1 to 8, wherein the cell aggregate including neural cells comprises cells that are positive for at least one of FOXA2, TH, and NURR1.

10. The method according to claim 9, wherein the cell aggregate including neural cells comprises cells positive for FOXA2 and LMX1A.

11. The method according to claim 9, wherein the cell aggregate including neural cells comprises cells positive for FOXA2, TH, and NURR1.

12. The method according to any one of claims 1 to 8, wherein the cell aggregate including neural cells comprises cells positive for FOXA2 and LMX1A in an amount of 40% or

more of the total cells and cells positive for TH and NURR1 in an amount of 40% or less of the total cells.

13. The method according to any one of claims 1 to 12, wherein the cell aggregate including neural cells comprises a dopamine-producing neuron progenitor cell and/or a dopamine-producing neuron.

14. The method according to any one of claims 1 to 13, wherein the cell aggregate includes 500 to 150000 cells.

15. The method according to any one of claims 1 to 14, wherein number of cells contained in the preservation solution is 80000 to 5000000 cells/mL, and the cell aggregate has an equivalent spherical diameter of 150 to 1000 μm.

16. The method according to any one of claims 1 to 15, wherein the cell aggregate and the preservation solution have volume of 0.25 mL to 2 mL.

17. The method according to any one of claims 1 to 16, wherein the cell aggregate and the preservation solution are packed in a 0.5 mL to 15 mL container.

18. A method for preserving a cell aggregate including neural cells and having a three-dimensional structure for a long-term, wherein the method comprises holding the frozen cell aggregate obtained by the method according to any one of claims 1 to 17 at or below −80°C.

19. The method according to any one of claims 1 to 18, wherein the obtained frozen cell aggregate can be used

without recovery culture after thawing.

20. A composition for transplantation, wherein the composition comprises, as an active ingredient, the cell aggregate frozen or preserved for a long-term by the method according to any one of claims 1 to 19.

21. A frozen composition for transplantation, wherein the composition comprises:

a cell aggregate including 60% or more of dopamine-producing neuron progenitor cells and dopamine-producing neurons derived from a pluripotent stem cell, having an equivalent spherical diameter of 150 μm to 1000 μm and including 500 to 150000 cells; and

a cryopreservation solution comprising 7% to 12% of dimethyl sulfoxide or propylene glycol and having the freezing point of −1°C to −10°C, and

wherein the frozen cell aggregate has following properties:

(1) about 60% or more of the total cells are viable after thawing;

(2) the cells after thawing have a neurite extension activity of 50% or more of that before freezing; and

(3) the rate of the FOXA2-positive cells, LMX1A-positive cells, NURR1-positive cells, and TH-positive cells in the cells viable after thawing are changed within ± 10% from those in the cells before freezing.

22. The composition for transplantation according to claim 20 or 21, wherein number of cells in the composition is 80000 to 5000000 cells/mL, and the composition comprises cells positive for FOXA2 and LMX1A in an amount of 40% or

more of the total cells and cells positive for TH and NURR1 in an amount of 40% or less of the total cells.

23. The composition for transplantation according to any one of claims 20 to 22, wherein the cell aggregate has an equivalent spherical diameter of 150 to 1000 μm.

24. The composition for transplantation according to any one of claims 20 to 23, wherein the composition can be used without recovery culture after thawing.

25. The composition for transplantation according to any one of claims 20 to 24, wherein the composition comprises 8 to 192 cell aggregates/mL, the cell aggregate has an equivalent spherical diameter of 150 μm to 1000 μm, and number of cells per container is 80000 to 2400000.

26. The composition for transplantation according to any one of claims 20 to 25, wherein the cell aggregate and the preservation solution have volume of 0.25 mL to 2 mL.

27. The composition for transplantation according to any one of claims 20 to 26, wherein the composition is packed in a 0.5 mL to 15 mL container.

28. A method for producing a composition for transplantation comprising a dopamine-producing neuron progenitor cell as an active ingredient, which comprises:

freezing a cell aggregate by the method according to any one of claims 1 to 17, wherein number of cells in the composition is 80000 to 5000000 cells/mL, the cell aggregate comprises cells positive for FOXA2 and LMX1A in an amount of 40% or more of the total cells and cells

positive for TH and NURR1 in an amount of 40% or less of the total cells, and the cell aggregate has an equivalent spherical diameter of 150 μm to 1000 μm.

29. The method for producing the composition for transplantation according to claim 28 containing an aggregate of neural cells as an active ingredient, wherein the composition comprises a population of cell aggregates which have an equivalent spherical diameter of 150 to 1000 μm, number of cells per container is 80000 to 2400000, the cell aggregate and the preservation solution have volume of 0.25 mL to 2 mL, and the composition is packed in a 0.5 mL to 15 mL container.

30. Use of the composition according to any one of claims 20 to 27 in the manufacture of a medicament~~A method~~ for treating a disease requiring regeneration of a dopamine-producing nerve, wherein the medicament is to be ~~which comprises following steps of:~~

~~(1)~~ thawed~~ing the composition for transplantation according to any one of claims 20 to 27~~ at 30°C to 40°C, preferably at 37°C ± 3°C~~,~~ and wherein the thawed medicament is to be

~~(2)~~ transplanted~~ing the composition for transplantation obtained in (1)~~ into a corpus striatum region of a patient.

31. The use~~method~~ according to claim 30, wherein the cryopreservation solution is to be replaced with a dosing vehicle without culture after thawing for subsequent transplantation~~to perform step (2)~~.